Pharmaceuticals

Health Annalisa Merelli

Withdrawal symptoms hit one in six patients stopping antidepressants, review finds

The Readout Jason Mast

STAT Plus: Testing begins for a new form of PrEP

Pharmalot Ed Silverman

STAT Plus: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits

Biotech Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care

Politics Sarah Owermohle

STAT Plus: Senators tussle over abortion policy against the backdrop of a presidential campaign

Pharmalot Ed Silverman

STAT Plus: U.S. drug shortages have reached a decade high and are lasting longer, too

The Readout Elaine Chen

STAT Plus: Operation Warp Speed but for rare disease

Biotech Angus Chen

STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

Pharma Andrew Joseph

STAT Plus: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug

Pharma Angus Chen

STAT Plus: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout Meghana Keshavan

STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates

Pharmalot Ed Silverman

STAT Plus: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program

Pharmalot Ed Silverman

STAT Plus: Many docs who tweeted product endorsements also took money from manufacturers, analysis shows

The Readout Elaine Chen

STAT Plus: Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week

The Readout Elaine Chen

STAT Plus: Wegovy linked to lower risk of alcohol use disorder in real-world study

Pharma Andrew Joseph

STAT Plus: Looking to expand its pipeline, Merck to buy eye-disease startup EyeBio

Special Report Anissa Durham

Black voices, Black bodies: Life in the age of Ozempic

The Readout Meghana Keshavan

STAT Plus: Biotech’s most interesting fundraisings from the last week

Biotech Andrew Joseph

STAT Plus: Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials

Biotech Jason Mast

STAT Plus: Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial

The Readout Meghana Keshavan

STAT Plus: More tumult at BIO amid the company’s fourth CEO in four years

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Pharma’s losing bet in New Jersey

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Listen: More tumult at BIO & coercive care for sickle cell patients

The Readout Elaine Chen

STAT Plus: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu

Biotech Allison DeAngelis and Elaine Chen

STAT Plus: Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy

Politics John Wilkerson

STAT Plus: FDA poised to publish guidelines for clinical trial diversity